Daoud Alia, Chu Quincy S
Department of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
Front Oncol. 2017 Sep 29;7:222. doi: 10.3389/fonc.2017.00222. eCollection 2017.
Discovery of the epidermal growth factor receptor gene mutation and the anaplastic lymphoma kinase chromosomal translocation in non-small cell lung cancer has prompted efforts around the world to identify many less common targetable oncogenic drivers. Such concerted efforts have been variably successful in both non-squamous and squamous cell carcinomas of the lung. Some of the targeted therapies for these oncogenic drivers have received regulatory approval for clinical use, while others have modest clinical benefit. In this mini-review, several of these targets will be reviewed.
非小细胞肺癌中表皮生长因子受体基因突变和间变性淋巴瘤激酶染色体易位的发现促使全球范围内努力识别许多不太常见的可靶向致癌驱动因素。这种协同努力在肺非鳞状细胞癌和鳞状细胞癌中取得了不同程度的成功。针对这些致癌驱动因素的一些靶向疗法已获得监管部门批准用于临床,而其他疗法的临床益处则较为有限。在这篇小型综述中,将对其中一些靶点进行综述。